Senti Biosciences, Inc.
SNTI evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for SNTI—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · SNTI
Senti Biosciences is a clinical-stage biotechnology company developing next-generation cell and gene therapies using its synthetic biology gene circuit platform, primarily targeting oncology indications with high unmet need.
Key risk: Going concern uncertainty
BioSniper Score
Based on 4 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 2 pipeline candidates · 1 clinical trial for Senti Biosciences, Inc..
Senti Biosciences is a clinical-stage biotechnology company developing next-generation cell and gene therapies using its synthetic biology gene circuit platform, primarily targeting oncology indications with high unmet need.
- Senti Biosciences is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with its gene circuit platform technologies for patients with incurable diseases [sec_mda · as of 2026-08-14].
- The company has incurred net losses of $17.0 million for the six months ended June 30, 2026, and had an accumulated deficit of $375.5 million as of that date [sec_mda · as of 2026-08-14].
- As of June 30, 2026, the company had cash and cash equivalents of $6.5 million, down from $16.4 million at December 31, 2025 [sec_mda · as of 2026-08-14].
- The company has not generated any revenue from product sales and expects to continue incurring net losses for the foreseeable future [sec_mda · as of 2026-08-14].
- Net cash used in operating activities was $21.7 million for the six months ended June 30, 2026 [sec_mda · as of 2026-08-14].
What works
- Senti Biosciences has built a synthetic biology platform that may enable programming of next-generation cell and gene therapies with gene circuits, potentially offering novel approaches to complex diseases [sec_mda · as of 2026-08-14].
- The company is advancing its gene circuit technologies in several oncology indications with high unmet need, suggesting a focused pipeline in areas of significant medical demand [sec_mda · as of 2026-08-14].
- The company generated $0.6 million in other income for the six months ended June 30, 2026, partly from subleasing portions of its headquarters, providing some non-dilutive cash inflow [sec_mda · as of 2026-08-14].
What to weigh
- Senti Biosciences has no approved products and has never generated revenue from product sales, with all losses stemming from R&D and G&A costs [sec_mda · as of 2026-08-14].
- The company's cash and cash equivalents declined from $16.4 million at December 31, 2025 to $6.5 million at June 30, 2026, indicating a rapid cash burn rate [sec_mda · as of 2026-08-14].
- The company has an accumulated deficit of $375.5 million as of June 30, 2026, reflecting substantial historical losses [sec_mda · as of 2026-08-14].
- Management has expressed substantial doubt about the company's ability to continue as a going concern, noting that additional capital is necessary to maintain operations [sec_mda · as of 2025-05-06].
From the filings
Quoted directly from source documents.
Senti Biosciences is a clinical-stage biotechnology company developing cell and gene therapies with gene circuits.
“We are a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with our gene circuit platform technologies for patients living with incurable diseases.”
SEC MD&A · August 14, 2026
The company had cash and cash equivalents of $6.5 million as of June 30, 2026.
“As of June 30, 2026 and December 31, 2025, we had cash and cash equivalents of $6.5 million and $16.4 million, respectively”
SEC MD&A · August 14, 2026
The company has incurred net losses of $17.0 million for the six months ended June 30, 2026.
“We have incurred net losses of $17.0 million and $28.8 million for the six months ended June 30, 2026 and 2025, respectively.”
SEC MD&A · August 14, 2026
The company has an accumulated deficit of $375.5 million as of June 30, 2026.
“accumulated deficit of $375.5 million and $358.6 million, respectively.”
SEC MD&A · August 14, 2026
Risks & what to watch (4)›
Key risks
- Going concern uncertainty — Management has expressed substantial doubt about the company's ability to continue as a going concern without additional capital [sec_mda · as of 2025-05-06].
- Cash burn and runway — Cash declined from $16.4M to $6.5M in six months; operating cash outflow was $21.7M in H1 2026 [sec_mda · as of 2026-08-14].
- No approved products or revenue — The company has no approved products and has never generated product revenue, relying entirely on financing [sec_mda · as of 2026-08-14].
- Clinical development uncertainty — Negative or inconclusive clinical trial results could lead to program delays or abandonment [sec_mda · as of 2026-05-14].
What to watch
- Ability to raise additional capital to fund ongoing operations and clinical development [sec_mda · as of 2026-08-14].
- Progress and results of preclinical and clinical studies for gene circuit product candidates [sec_mda · as of 2026-08-14].
- Changes in cash position and burn rate, especially given the decline from $16.4M to $6.5M in six months [sec_mda · as of 2026-08-14].
- Any partnership, licensing, or sublease income that could extend the cash runway [sec_mda · as of 2026-08-14].
Sources: SEC MD&A · Generated August 27, 2026 · How we verify sources →
Run Senti Biosciences, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Senti Biosciences, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
2.0 months
OCF -$14M · Net income -$13M
Lead: Phase 1
2 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Pipeline
Regulatory
Financials
Short Interest
as of Apr 21, 2026- % of float
- 2.4%
- Days to cover
- 6.8
- Shares short
- 736,084
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
SNTI short interestGovernance
Frequently asked questions
What is the AI investment thesis for Senti Biosciences, Inc.?
Senti Biosciences is a clinical-stage biotechnology company developing next-generation cell and gene therapies using its synthetic biology gene circuit platform, primarily targeting oncology indications with high unmet need.
What is Senti Biosciences, Inc.'s lead drug candidate?
Senti Biosciences, Inc.'s most advanced tracked candidate is senti-202 (Phase 1) for AML/MDS.
Who is the CEO of Senti Biosciences, Inc.?
Dr. Timothy K. Lu M.D., Ph.D. is the chief executive officer of Senti Biosciences, Inc. (SNTI).
Where is Senti Biosciences, Inc. headquartered?
Senti Biosciences, Inc. (SNTI) is headquartered in South San Francisco, CA, United States.
What therapeutic areas does Senti Biosciences, Inc. focus on?
Senti Biosciences, Inc. develops therapies across Oncology, Gene Therapy.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.